company background image
CSTL

Castle Biosciences NasdaqGM:CSTL Stock Report

Last Price

US$33.94

Market Cap

US$892.5m

7D

11.1%

1Y

-47.3%

Updated

14 Aug, 2022

Data

Company Financials +
CSTL fundamental analysis
Snowflake Score
Valuation2/6
Future Growth1/6
Past Performance0/6
Financial Health5/6
Dividends0/6

CSTL Stock Overview

Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers.

Castle Biosciences, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Castle Biosciences
Historical stock prices
Current Share PriceUS$33.94
52 Week HighUS$78.59
52 Week LowUS$15.58
Beta1.17
1 Month Change37.24%
3 Month Change74.23%
1 Year Change-47.33%
3 Year Change67.61%
5 Year Changen/a
Change since IPO58.60%

Recent News & Updates

Aug 14
Analysts Just Published A Bright New Outlook For Castle Biosciences, Inc.'s (NASDAQ:CSTL)

Analysts Just Published A Bright New Outlook For Castle Biosciences, Inc.'s (NASDAQ:CSTL)

Castle Biosciences, Inc. ( NASDAQ:CSTL ) shareholders will have a reason to smile today, with the analysts making...

Aug 08

Castle Biosciences Q2 2022 Earnings Preview

Castle Biosciences (NASDAQ:CSTL) is scheduled to announce Q2 earnings results on Monday, August 8th, after market close. The consensus EPS Estimate is -$0.80 (-128.6% Y/Y) and the consensus Revenue Estimate is $28.37M (+24.6% Y/Y). Over the last 3 months, EPS estimates have seen 0 upward revisions and 3 downward. Revenue estimates have seen 3 upward revisions and 2 downward.

Aug 05
Is There Now An Opportunity In Castle Biosciences, Inc. (NASDAQ:CSTL)?

Is There Now An Opportunity In Castle Biosciences, Inc. (NASDAQ:CSTL)?

Castle Biosciences, Inc. ( NASDAQ:CSTL ), is not the largest company out there, but it received a lot of attention from...

Shareholder Returns

CSTLUS HealthcareUS Market
7D11.1%2.3%3.2%
1Y-47.3%14.7%-10.2%

Return vs Industry: CSTL underperformed the US Healthcare industry which returned 14.7% over the past year.

Return vs Market: CSTL underperformed the US Market which returned -10.2% over the past year.

Price Volatility

Is CSTL's price volatile compared to industry and market?
CSTL volatility
CSTL Average Weekly Movement13.9%
Healthcare Industry Average Movement8.8%
Market Average Movement7.7%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: CSTL is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.

Volatility Over Time: CSTL's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2007482Derek Maetzoldhttps://castlebiosciences.com

Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient’s tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary GEP test to diagnose suspicious pigmented lesions.

Castle Biosciences, Inc. Fundamentals Summary

How do Castle Biosciences's earnings and revenue compare to its market cap?
CSTL fundamental statistics
Market CapUS$892.52m
Earnings (TTM)-US$44.49m
Revenue (TTM)US$110.20m

8.1x

P/S Ratio

-20.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CSTL income statement (TTM)
RevenueUS$110.20m
Cost of RevenueUS$22.73m
Gross ProfitUS$87.48m
Other ExpensesUS$131.97m
Earnings-US$44.49m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.69
Gross Margin79.38%
Net Profit Margin-40.37%
Debt/Equity Ratio0%

How did CSTL perform over the long term?

See historical performance and comparison